FGF8 induces epithelial-mesenchymal transition and promotes metastasis in oral squamous cell carcinoma

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common cancers worldwide, and with 354 864 new cases each year. Cancer metastasis, recurrence, and drug resistance are the main causes to cripples and deaths of OSCC patients. As potent growth factors, fibroblast growth factors (FGFs) are frequently susceptible to being hijacked by cancer cells. In this study, we show that FGF8 is upregulated in OSCC tissues and high FGF8 expression is related with a set of clinicopathologic parameters, including age, drinking, and survival time. FGF8 treatment enhances the invasive capability of OSCC cells. Lentivirus-based FGF8 expression promotes OSCC metastasis in a mouse lung metastasis model. Further, mechanistic study demonstrates that FGF8 induces epithelial–mesenchymal transition (EMT) in OSCC cells. These results highlight a pro-metastatic function of FGF8, and underscore the role of FGF8 in OSCC development.

References

[1] Bray F, . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin., 2018, 68: 394-424.

[2] Jemal A, . Global cancer statistics. Cancer J. Clin., 2011, 61: 69-90.

[3] Zhou Y, . Vesicular stomatitis virus matrix protein (VSVMP) inhibits the cell growth and tumor angiogenesis in oral squamous cell carcinoma. Oral Oncol., 2012, 48: 110-116.

[4] Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma—an update. Cancer J. Clin., 2015, 65: 401-421.

[5] Siegel RL, Miller KD, Jemal A. Cancer statistics. Cancer J. Clin., 2015, 65: 5-29.

[6] Torre LA, . Global cancer statistics, 2012. Cancer J. Clin., 2015, 65: 87-108.

[7] Aires F, Lin C, Matos L, Kulcsar M, Cernea C. Risk factors for distant metastasis in patients with oral cavity squamous cell carcinoma undergoing surgical treatment. ORL, 2017, 79: 347-355.

[8] Arun I, . Lymph node characteristics and their prognostic significance in oral squamous cell carcinoma. Head Neck, 2021, 43: 520-533.

[9] Takes RP, . Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol., 2012, 48: 775-779.

[10] Zhang WB, Peng X, Eisele DW. Cervical metastases of oral maxillary squamous cell carcinoma: a systematic review and meta‐analysis. Head Neck, 2016, 38: E2335-E2342.

[11] Miguel AFP, Mello FW, Melo G, Rivero ERC. Association between immunohistochemical expression of matrix metalloproteinases and metastasis in oral squamous cell carcinoma: systematic review and meta‐analysis. Head Neck, 2020, 42: 569-584.

[12] Yuan Y, . LRP6 is identified as a potential prognostic marker for oral squamous cell carcinoma via MALDI-IMS. Cell Death Dis., 2017, 8

[13] Fridman E, . The role of adjuvant treatment in early-stage oral cavity squamous cell carcinoma: an international collaborative study. Cancer, 2018, 124: 2948-2955.

[14] Jansen L, . Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site. Oral Oncol., 2018, 76: 8-15.

[15] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov., 2009, 8: 235-253.

[16] Xie Y, . FGF/FGFR signaling in health and disease. Signal Transduct. Target. Ther., 2020, 5: 181.

[17] Neugebauer JM, Amack JD, Peterson AG, Bisgrove BW, Yost HJ. FGF signalling during embryo development regulates cilia length in diverse epithelia. Nature, 2009, 458: 651-654.

[18] Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation, 2010, 75: 831-842.

[19] Krejci P, Prochazkova J, Bryja V, Kozubik A, Wilcox WR. Molecular pathology of the fibroblast growth factor family. Hum. Mutat., 2010, 30: 1245-1255.

[20] Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 2010, 10: 116-129.

[21] Liu R, . FGF8 promotes colorectal cancer growth and metastasis by activating YAP1. Oncotarget, 2015, 6: 935-952.

[22] Tang S, Hao Y, Yuan Y, Liu R, Chen Q. The roles of fibroblast growth factor receptor 4 in cancers. Cancer Sci., 2018, 109: 3024-3031.

[23] Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr. Relat. Cancer, 2004, 11: 709.

[24] Matsuike A, Ishiwata T, Watanabe M, Asano G. Expression of fibroblast growth factor (FGF) -10 in human colorectal adenocarcinoma cells. J. Nippon Med. Sch., 2001, 68: 397-404.

[25] Hao Y, Tang S, Yuan Y, Liu R, Chen Q. Roles of FGF8 subfamily in embryogenesis and oral‑maxillofacial diseases. Int. J. Oncol., 2019, 54: 797-806.

[26] Valta MP, . FGF‐8 is involved in bone metastasis of prostate cancer. Int. J. Cancer, 2008, 123: 22-31.

[27] Song Z, . The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res., 2000, 60: 6730-6736.

[28] Mattila MA, Härkönen P. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev., 2007, 18: 257-266.

[29] Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol., 2009, 45: 309-316.

[30] Qiao B, Johnson NW, Gao J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-β1 is Snail family-dependent and correlates with matrix metalloproteinase-2 and-9 expressions. Int. J. Oncol., 2010, 37: 663-668.

[31] Wang Y, . Role of the EZH2/miR-200 axis in STAT3-mediated OSCC invasion. Int. J. Oncol., 2018, 52: 1149-1164.

[32] Chen Q, . Photodynamic therapy guidelines for the management of oral leucoplakia. Int. J. Oral. Sci., 2019, 11: 14.

[33] Nath RG, Ocando JE, Guttenplan JB, Chung F. 1, N2-propanodeoxyguanosine adducts: potential new biomarkers of smoking-induced DNA damage in human oral tissue. Cancer Res., 1998, 58: 581-584.

[34] Berdan CA, Tangney CC, Scala C, Stolley M. Childhood cancer survivors and adherence to the American Cancer Society Guidelines on Nutrition and Physical Activity. J. Cancer Surviv., 2014, 8: 671-679.

[35] Oliveira MLC, . A 10-year analysis of the oral squamous cell carcinoma profile in patients from public health centers in Uruguay. Braz. Oral Res., 2015, 29: 1-8.

[36] Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev., 2016, 35: 645-654.

[37] Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene, 2008, 27: 6958-6969.

[38] Gloushankova NA, Zhitnyak IY, Rubtsova SN. Role of epithelial-mesenchymal transition in tumor progression. Biochemistry, 2018, 83: 1469-1476.

[39] Ievgenia P, Cédric B. EMT transition states during tumor progression and metastasis. Trends Cell Biol., 2018, 29: 212-226.

[40] Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front. Med., 2018, 12: 361-373.

[41] Li Q, . Increased expression of high-mobility group nucleosomal-binding domain 2 protein in various tumor cell lines. Oncol. Lett., 2018, 15: 4517-4522.

[42] Yan Ming, . Correlation of NF-kB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma. BMC Cancer, 2010, 10

[43] Lee JH, . EGFR-phosphorylated platelet isoform of phosphofructokinase 1 promotes PI3K activation. Mol. Cell, 2018, 70: 197-210.

[44] Cliff ZQ, . PrePPI: a structure-informed database of protein–protein interactions. Nucleic Acids Res., 2013, 41: D828-D833.

[45] Yuan Y, . Proteomic identification of cyclophilin A as a potential biomarker and therapeutic target in oral submucous fibrosis. Oncotarget, 2016, 7: 60348-60365.

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81321002, 81672674)

Young Elite Scientist Sponsorship Program by cst(2016QNRC001) and the 111 Project of MOE China (Grant No. B14038).